

## **Mouse IL-2 Biotinylated Antibody**

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: BAF402

DESCRIPTION	
Species Reactivity	Mouse
Specificity	Detects mouse IL-2 in ELISAs and Western blots. In western blots, less than 10% cross-reactivity with rhIL-2, rpIL-2 and rrIL-2 is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	E. coli-derived recombinant mouse IL-2 (R&D Systems, Catalog # 402-ML) Ala21-Gln169 Accession # P04351
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details.

## **APPLICATIONS**

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	0.1 μg/mL	Recombinant Mouse IL-2 (Catalog # 402-ML)
Mouse IL-2 Sandwich Immunoassay		Reagent
ELISA Capture	2-8 μg/mL	Mouse IL-2 Antibody (Catalog # MAB702)
ELISA Detection	0.1-0.4 µg/mL	Mouse IL-2 Biotinylated Antibody (Catalog # BAF402)
Standard		Recombinant Mouse IL-2 (Catalog # 402-ML)

PREPARATION AND STORAGE		
Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.	
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.	
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.  12 months from date of receipt, -20 to -70 °C as supplied.  1 month, 2 to 8 °C under sterile conditions after reconstitution.  6 months, -20 to -70 °C under sterile conditions after reconstitution.	

## BACKGROUND

Interleukin-2 (IL-2) is a O-glycosylated four  $\alpha$ -helix bundle cytokine that has potent stimulatory activity for antigen-activated T cells. It is expressed by CD4<sup>+</sup> and CD8<sup>+</sup> T cells,  $\gamma\delta$  T cells,  $\beta$  cells, dendritic cells, and eosinophils (1 - 3). Mature mouse IL-2 shares 56% and 73% as sequence identity with human and rat IL-2, respectively. It shows strain-specific heterogeneity in an N-terminal region that contains a poly-glutamine stretch (4). Mouse and human IL-2 exhibit cross-species activity (5). The receptor for IL-2 consists of three subunits that are present on the cell surface in varying preformed complexes (6 - 8). The 55 kDa IL-2 R $\alpha$  is specific for IL-2 and binds with low affinity. The 75 kDa IL-2 R $\beta$ , which is also a component of the IL-15 receptor, binds IL-2 with intermediate affinity. The 64 kDa common gamma chain  $\gamma$ c/IL-2 R $\gamma$ , which is shared with the receptors for IL-4, -7, -9, -15, and -21, does not independently interact with IL-2. Upon ligand binding, signal transduction is performed by both IL-2 R $\beta$  and  $\gamma$ c. IL-2 is best known for its autocrine and paracrine activity on T cells. It drives resting T cells to proliferate and induces IL-2 and IL-2 R $\alpha$  synthesis (1, 2). It contributes to T cell homeostasis by promoting the Fas-induced death of naïve CD4<sup>+</sup> T cells but not activated CD4<sup>+</sup> memory lymphocytes (9). IL-2 plays a central role in the expansion and maintenance of regulatory T cells, although it inhibits the development of Th17 polarized cells (10 - 12). Thus, IL-2 may be a key cytokine in the natural suppression of autoimmunity (13, 14).

## References:

- 1. Ma, A. et al. (2006) Annu. Rev. Immunol. 24:657.
- 2. Gaffen, S.L. and K.D. Liu (2004) Cytokine 28:109.
- 3. Kashima, N. et al. (1985) Nature 313:402.
- 4. Matesanz, F. et al. (1993) Immunogenetics 38:300.
- Mosmann, T.R. et al. (1987) J. Immunol. 138:1813.
- 6. Liparoto, S.F. et al. (2002) Biochemistry 41:2543.
- Wang, X. et al. (2005) Science 310:1159.
- 8. Bodnar, A. et al. (2008) Immunol. Lett. 116:117.
- 9. Jaleco, S. et al. (2003) J. Immunol. 171:61.
- 10. Malek, T.R. (2003) J. Leukoc. Biol. **74**:961.
- Laurence, A. et al. (2007) Immunity 26:371.
   Kryczek, I. et al. (2007) J. Immunol. 178:67
- Kryczek, I. *et al.* (2007) J. Immunol. **178**:6730.
   Afzali, B. *et al.* (2007) Clin. Exp. Immunol. **148**:32.
- 14. Fehervari, Z. *et al.* (2006) Trends Immunol. **27**:109.

Rev. 2/6/2018 Page 1 of 1

